Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Quotes

Analysis

Analyst Ratings

News

Press Releases

Twitter

Media Mentions

Ownership

Earnings

Astrazeneca PLC (AZN) 52.68 0.61
Price Open:51.98Day's Range:43.21000 - 52.72000
Price Close:51.7152wk Range:39.72 - 52.72000
Price Day Change:0.61Volume:2,667,852
Price % Change:1.18Market Cap:65.400B
Bid:52.30000PE Ratio:11.44
Ask:52.68000EPS Diluted:4.521
Trade AZN NOW!

The Latest On AZN

Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013 5/21/13 9:26am
U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying 5/18/13 3:54pm
Benzinga's M&A Chatter for Wednesday May 15, 2013 5/15/13 6:52pm
Benzinga's M&A Chatter for Monday May 13, 2013 5/13/13 5:55pm
Under The Hood: An ETF For International Income 4/18/13 3:33pm
A Peek Into The Market Before The Trading Starts 4/5/13 7:17am
AstraZeneca Announces Results from OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis 4/5/13 5:58am
A Peek Into The Market Before The Trading Starts 4/3/13 7:39am
Astrazeneca's Medimmune Biologics Unit Acquires Alphacore Pharma 4/3/13 7:02am
Actavis Confirms Court Issues TRO Preventing Distribution of Generic Pulmicort RESPULES 4/3/13 6:37am
Benzinga's Top Upgrades 4/2/13 7:10am
Actavis Confirms Favorable Court Ruling in Patent Suit Involving Generic Version of AstraZeneca's Pulmicort RESPULES 4/1/13 7:14pm
more
Press Releases
Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013 5/21/13 Business Wire
Assessing Your Asthma is Key to Taking Control 5/13/13 Newswire
Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month Period 5/6/13 Business Wire
AstraZeneca to Establish Strategic R&D Center in Gaithersburg, Md; Wilmington Remains North America Commercial Headquarters 3/18/13 Business Wire
AstraZeneca Encourages Atherosclerosis Education among High Risk Patients during American Heart Month 2/14/13 Newswire
AstraZeneca Recognized as a Top Company for Female Executives 2/5/13 Business Wire
BRILINTA (Ticagrelor) Receives Additional Class I Recommendation in Updated ACCF/AHA Guidelines for the Management of STEMI Patients 12/17/12 Business Wire
CRESTOR® US Patent Upheld by Court of Appeals for the Federal Circuit 12/14/12 Business Wire
AstraZeneca Updates US Label For FASLODEX® (fulvestrant) Injection 12/5/12 Business Wire
Final Overall Survival Analysis of CONFIRM Shows a 4.1 Month Difference in Median Overall Survival When Using FASLODEX® (fulvestrant) Injection 500 mg Compared with 250 mg.1,2 12/5/12 Business Wire
AstraZeneca to Present Key New Data for Hormone Receptor-Positive Metastatic Breast Cancer at the 35th CTRC-AACR Annual San Antonio Breast Cancer Symposium 12/4/12 Business Wire
AstraZeneca Makes Major Commitment to Help Patients with Acute Coronary Syndrome Have BRILINTA (ticagrelor) Available in Their Local Communities 12/4/12 Business Wire

Get the latest AZN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Astrazeneca PLC stock price.

Partner Headlines
Bulls taking Control of AstraZeneca? 5/22/13
My 4 Favorite Dividend Growth Stocks from Abroad 5/20/13
AstraZeneca - Shares Seeking Direction 5/17/13
Good News for Roche's Tarceva - Analyst Blog 5/16/13
Cheerleaders: Look Beyond Pharma For Jobs 5/16/13
My 3 Favorite Foreign Stocks with Cheap Valuation and Great Yields 5/15/13
Wider-than-Expected Loss at Optimer - Analyst Blog 5/10/13
"Marketing Without Innovation": a Merck Story 5/10/13
Pharma's Failure: Drug Spending Finally Declines 5/9/13
Narrower-Than-Expected Loss at Rigel Pharma - Analyst Blog 5/9/13
Will DENTSPLY Beat Earnings in 1Q? - Analyst Blog 5/8/13
The New Diet Pill Players: Arena and Vivus 5/8/13